Diamyd, Inc. (formerly Nurel Therapeutics)

Diamyd, Inc. (formerly Nurel Therapeutics) is a gene therapy company acquired by Diamyd Medical AB in December 2005. Originally focused on a proprietary targeted drug delivery technique called Nerve-Targeted Gene Delivery, the company was subsequently integrated into Diamyd Medical's diabetes pipeline.